Clinical trial
Recombinant Human Relaxin for the Treatment of Decompensated CHF
NCT00406575 · Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies, Industry · Terminated
Key facts
| NCT number | NCT00406575 |
|---|---|
| Title | Recombinant Human Relaxin for the Treatment of Decompensated CHF |
| Official title | A Phase II Randomized, Double Blind, Placebo-Controlled Study of Recombinant Human Relaxin in Patients With Decompensated Congestive Heart Failure |
| Lead sponsor | Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Congestive Heart Failure (CHF) |
| Intervention type | Drug |
| Interventions | Placebo, Recombinant human relaxin (rhRlx) |
| Enrollment | 11 |
| Start date | Nov 1, 2006 |
| Primary completion | Jan 1, 2007 |
| Completion | Jan 1, 2007 |
| First posted | Dec 4, 2006 |
| Last update posted | May 7, 2014 |
| Countries | Russia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: